Date: 2016-03-07
Type of information: Nomination
Compound:
Company: Avexis (USA - IL)
Therapeutic area: Rare diseases - Genetic diseases - Neurological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On March 07, 2016, AveXis, a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, announced three appointments to its Board of Directors: Daniel G. Welch, Terrence C. Kearney and Frank Verwiel, M.D., who joined the Board of Directors prior to the company’s initial public offering. Mr. Welch is serving as Non-executive Chairman of the Board. Daniel Welch has more than 35 years of healthcare experience at multi-national pharmaceutical and biotechnology companies. He is an executive partner at Sofinnova Ventures, a position he has held since January 2015. He previously served as the President, Chief Executive Officer and a director of InterMune, Inc. from September 2003 to September 2014, and from May 2007 to September 2014 also served as the company’s Chairman of the board of directors. From August 2002 to January 2003, Mr. Welch served as Chairman and Chief Executive Officer of Triangle Pharmaceuticals, Inc. In addition to AveXis, Mr. Welch currently serves on the boards of directors of Seattle Genetics, Inc., Ultragenyx Pharmaceutical Inc., where he also serves as Chairman, and Intercept Pharmaceuticals, Inc. He previously served on the board of directors of Hyperion Therapeutics, Inc. from 2012 to 2015. Terrence C. Kearney has more than 30 years of global healthcare experience at major pharmaceutical and life sciences companies, most recently as the Chief Operating Officer for Hospira, Inc. where he previously held the position of Chief Financial Officer. Prior to Hospira, Mr. Kearney worked for 25 years in a variety of financial management roles at Abbott Laboratories. In addition to AveXis, Mr. Kearney currently serves on the Boards of Directors of Vertex Pharmaceuticals, Innoviva (formerly known as Theravance Inc.) and Acceleron Pharma. Frank Verwiel, M.D. has more than 25 years of experience in the pharmaceutical industry, most recently as President, Chief Executive Officer and member of the Board of Directors of Aptalis Pharma Inc. (formerly known as Axcan Pharma). He has also held a variety of international management positions at Merck & Co. Inc. and Servier Laboratories. Dr. Verwiel previously served on the Board of Directors of InterMune, Inc. Dr. Verwiel was also a member of the Board of Directors of the Biotechnology Industry Organization (BIO). He currently serves on the Boards of Directors of Achillion Pharmaceuticals Inc. and Obseva SA, and is also an observer of the Board of Directors
Financial terms:
Latest news:
